Lessons from uncertainty on antifungal treatment in ICU

Cortegiani, Andrea; Russotto, Vincenzo; Giarratano, Antonino

doi:10.21037/jtd.2017.03.65

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one RCT evaluated the preemptive approach with beta-D-glucan, while it included few patients and had an inadequate design. These findings were recently confirmed in the most recent RCT on this subject by Timsit et al, which recruited 260 nonneutropenic critically ill patients with ICU-acquired sepsis, multiple-site Candida colonization, multiple organ failure, and broadspectrum antibiotic therapy (23,24).…”

Section: Updated Evidencementioning

confidence: 66%

What Is the Most Recent Evidence on the Prevention and Early Treatment of Invasive Fungal Infections in Nonneutropenic Critically Ill Patients?

Cortegiani

Russotto

Iozzo

et al. 2017

Arch Clin Infect Dis

Self Cite

View full text Add to dashboard Cite

Invasive fungal infections (IFIs) are associated with high morbidity and mortality in intensive care units. Candida species are the most important fungal pathogens and among the most frequent causes of infection in critically ill patients. Studies have evaluated the correlation between the onset of antifungal treatment and survival. However, definitive diagnosis of IFI is time-consuming in clinical practice. Antifungal prophylaxis and preemptive or empirical treatments are among therapeutic strategies to prevent or treat early fungal infections in selected patients. Recently, new evidence from randomized controlled trials and systematic reviews has been published. Moreover, new clinical practice guidelines from international communities are available. The aim of this review was to present updated evidence on this topic.

show abstract

Section: Updated Evidencementioning

confidence: 66%